Interstitial Cystitis Drug Market TOC
Market Value (USD Million), CAGR, 2024-2037F
Cross Analysis of Route of Administration w.r.t. Distribution Channel
Cross Analysis of Route of Administration w.r.t. Distribution Channel
Rest of Latin America, Market Value (USD Million), CAGR, 2024-2037F
Interstitial Cystitis Drugs Market size is anticipated to reach USD 2.61 Billion by the end of 2037, expanding at around 5.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2024, the industry size of interstitial cystitis drugs is assessed at USD 1.31 Billion.
The main reason propelling the interstitial cystitis drugs market expansion is the rising incidence of interstitial cystitis. For example, research released in August 2022 by the National Center for Biotechnology Data projected that 2.6 instances of interstitial cystitis per 100,000 women annually occur in the United States. The research also said that, compared to Japan, where the reported incidence rate was just 3–4 cases per 100,000 women yearly, Europe had a larger incidence rate-18 cases per 100,000 women.
The Internet of Things, wearable technology, virtual reality, and information technology have all altered daily life and changed hospital operations. A promising trend in healthcare is the application of artificial intelligence, which has the potential to greatly enhance the delivery of real-time, individualized treatment alternatives.
Artificial intelligence (AI) has been incorporated into urology research and practice to increase the accuracy of illness detection and create prediction models for tracking therapy response.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025 - 2036 |
|
CAGR |
5.4% |
|
Base Year Market Size (2024) |
USD 1.31 billion |
|
Forecast Year Market Size (2037) |
USD 2.61 billion |
|
Regional Scope |
|
Route of Administration (Oral, Parental, Intravesical Administration)
By 2037, oral segment in the interstitial cystitis drugs market is estimated to cross USD 1.9 Billion. Route of administration is considered one of the most common routes of administration in interstitial cystitis drugs due to the ease of administration, and availability of drugs such as TCAs. The route of administration for IC medicinal products is different, with oral drugs and intravesical treatments being preferred.
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
In interstitial cystitis drugs market, hospital segment is expected to exceed USD 1.36 Billion by 2037. Hospital pharmacies are expected to dominate the market over the forecast period, in view of an increasingly large number of hospitals worldwide which will undoubtedly increase their demand for hospital pharmacies.
In the United States, there are 6120 hospitals, according to an annual survey of hospitals in the USA is conducted by the American Hospital Association.
Our in-depth analysis of the global interstitial cystitis drugs market includes the following segments:
|
Drug Class |
|
|
Route of Administration |
|
|
Mode of Purchase |
|
|
Distribution Channel |
|
North American Market Forecast
North America interstitial cystitis drugs market size is set to cross USD 1.02 Billion by 2037. Various factors, such as an increase in research cooperation among institutes and organizations, have led to the growth of this market. In the case of Lipella Pharmaceuticals, Inc., a biotechnology company, in September 2023 it launched an R&D study with researchers at the University of Pittsburgh USA. The study aims to identify different types of interstitial cystitis and urinary tract pain syndrome and the study is currently at an early stage.
Various factors, including an increase in the incidence of interstitial cystitis and an increase in research and development in the field of interstitial cystitis drugs by organizations and research institutes, have contributed to the growth of the interstitial cystitis drugs market in the United States.
The demand for inspiratory cystitis drugs is driven by an increase in the incidence of it in the Canada country. Companies are working on new treatments with fewer side effects, such as regeneration and gene therapy, because of the limited availability of existing treatment options for idiopathic cystitis.
European Market Statistics
Interstitial cystitis drugs market size for Europe region is expected to reach USD 620 million by the end of 2037. The market has been on the rise due to the increasing prevalence of the condition. For example, according to a survey conducted in Europe, the estimated mortality is 300 / 100 000 in Finland, 206 / 100 000 in Austria, and 147 / 100 000 in Boston.
According to a global survey, Germany is the country with the highest average patient enrolment of interstitial cystitis clinical trials in November 2023, after the United States. The main reason for the increasing prevalence of this condition is the increasing number of women in Europe, especially middle-aged and older women.
Infrastructure changes in the healthcare system can lead to improved diagnosis and treatment of interstitial cystitis, which can be expected to lead to growth in the United Kingdom.
In response to the problems of existing interstitial cystitis drugs, companies in Germany are developing novel therapeutic approaches with fewer side effects, such as regenerative therapy and gene therapy.
Companies are developing novel treatments with fewer side effects, e.g. regeneration therapy and gene therapy, as a result of the limited availability of existing treatment options for interstitial cystitis in France. Demand will increase as a result of the development of such therapies. As a result, due to the increasing incidence of interstitial cystitis and the introduction of gene therapy, the market for interstitial cystitis medicinal products will increase.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?